GLP1R and diabetes mellitus: In the interim, the use of diabetes medications like pioglitazone or GLP-1 RAs, with semaglutide having the strongest evidence, should be considered more frequently by clinicians, as these medications have demonstrated the ability to reverse steatohepatitis in controlled clinical trials involving subjects with or without diabetes over a period of 1.5 to 3 years (112, 113).